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introduction: Encapsulation of biologically active molecules into nanoparticles (NPs), for 
site-specific delivery, is a fast growing area. These NPs must be biocompatible, non-toxic, 
and able to release their load in a controlled way. We have developed a series of NPs 
based on (bio)degradable and biocompatible poly(malic acid) derivatives, poly(benzyl 
malate) (PMLABe), with its PEG-grafted stealth analog and target-specific biotin-PEG-b-
PMLABe one. A lipophilic radiotracer has then been encapsulated into these NPs.
Methods: Monomers were synthesized from dl-aspartic acid. PEG42-b-PMLABe73 
and Biot-PEG66-b-PMLABe73 block copolymers were obtained by anionic ring-opening 
polymerization of benzyl malolactonate in presence of α-methoxy-ω-carboxy-PEG42 and 
α-biotin-ω-carboxy-PEG66 as initiators. NPs were prepared by nanoprecipitation. Size, 
polydispersity, and zeta potential were measured by dynamic light scattering (DLS) and 
zetametry. 99mTc-SSS was prepared as previously described. Encapsulation efficacy was 
assessed by varying different parameters, such as encapsulation with preformed NPs 
or during their formation, influence of the solvent, and of the method to prepare the 
NPs. After decay, 99mTc-loaded NPs were also analyzed by DLS and zetametry. NPs’ 
morphology was assessed by transmission electron microscopy.
results: 99mTc-SSS was added during nanoprecipitation, using two different methods, 
to ensure good encapsulation. Radiolabeled NPs present increased diameters, with 
identical low polydispersity indexes and negative zeta potentials in comparison to 
non-radiolabeled NPs.
conclusion: A radiotracer was successfully encapsulated, but some further optimization 
is still needed. The next step will be to modify these radiolabeled NPs with a hepatotrope 
peptide, and to replace 99mTc with 188Re for therapy. Our team is also working on drugs’ 
encapsulation and grafting of a fluorescent probe. Combining these modalities is of inter-
est for combined chemo-/radiotherapy, bimodal imaging, and/or theranostic approach.
Keywords: functional nanoparticles, site-specific targeting, degradable poly(benzyl malate) derivatives, 
radionuclide encapsulation, technetium-99m
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introduction
Nanomedicine, the use of nanoparticles (NPs) in medicine, is an 
ever-growing research field as illustrated by the huge amount of 
scientific publications and the important number of formulations 
registered for clinical trials, especially for cancer therapies (1). 
Such a growing interest results from the urgent need for highly 
efficient anti-cancer drug delivery systems allowing an increased 
efficacy of the drugs together with a decrease of their non-specific 
distribution and toxicity (2–4). Indeed, despite better knowledge 
and understanding of cancer biology, significant improvements 
in cancer treatments are still needed, specifically to address a 
large amount of drugs at the site of action, to decrease their toxic 
side effects and to simplify the administration protocols. In this 
context, nanoparticulate systems (liposomes, micelles, polymer-
based NPs, etc.) have attracted the interest of many researchers 
and numerous systems have been developed (1). However, the 
prepared NPs have to answer to very strict specifications: (i) they 
have to be non-toxic and biocompatible at any stage of their life, 
until their complete excretion from the body; (ii) they need to have 
stealth properties and reduced immunogenicity together with 
ability to carry large amount of drug and to deliver it at a specific 
site in a sustainable way. Even if undeniable progresses have been 
achieved in the design of the ideal drug carriers as evidenced by the 
Food and Drug Administration (FDA) approval obtained by some 
nanovectors and by the number of NPs in preclinical or clinical 
phases (1, 5, 6), several properties, such as biocompatibility, drug 
loading capacity and site-specificity of drug release, need to be 
further improved. Among the nanoplatforms designed to address 
these objectives, polymer-based NPs have attracted much interest 
mainly because of the versatile characteristics of polymers allow-
ing adjustment of the physico-chemical and biological properties 
of the corresponding nanocarriers. Consequently, several families 
of polymers have been developed to formulate multifunctional 
drug carriers with properties adjusted to the considered applica-
tion (2). However, when designing a polymer family, one must 
keep in mind that the resulting materials are prepared to be used 
in vivo and that they have to respect the very strict specifications 
defined above. Another property which can be of importance 
is the (bio)degradability of the polymers constituting the drug 
delivery systems, allowing their elimination thanks to the (bio)
degradation of the copolymers constituting the NPs, thus avoid-
ing NPs accumulation in the body. However, this means that the 
degradation process must lead to non-immunogenic, biocompat-
ible, and/or (bio)assimilable low molecular weight molecules that 
can be eliminated from the body. In this context, several (bio)
degradable polymers have been developed and formulated under 
various nanoplatforms with more or less success (7, 8).
Therefore, the design of (bio)degradable polymers, whose 
physico-chemical and biological properties can be adjusted 
either by copolymerization, chemical modifications, or both, is 
of great importance (9, 10). Poly(β-malic acid) (PMLA) is a very 
good candidate due to the presence of carboxylic acid pendant 
groups, which can be chemically modified to introduce molecules 
of interest, and ester cleavable bounds within the polymer back-
bone, allowing the degradation of the polymer main chain into 
biocompatible metabolites (11–13).
Recently, we have synthesized and characterized two 
amphiphilic derivatives of PMLA presenting stealth properties, 
the poly(ethylene glycol)-b-poly(benzyl malate) (PEG42-b-
PMLABe73), and targeting properties, the biotin-PEG66-b-PM-
LABe73. These block copolymers are able to self-assemble in 
aqueous media, leading to well-defined NPs designed for site-
specific sustainable drug release in the frame of hepatocellular 
carcinoma (HCC). We showed that an anti-cancer drug model, 
the Doxorubicin (Dox), can be encapsulated into both stealth and 
targeted NPs with quite high encapsulation efficiency (14, 15) and 
that both kind of empty NPs have no significant toxicity against 
normal and cancer cell lines even at high concentrations (14–16).
Among molecules of interest to be encapsulated, one can 
include radioisotopes, either for imaging (diagnostic) or 
therapy, or even both (theranostics). There is an abundant, and 
ever-growing literature on the subject (17–23). All types of NPs 
have been radiolabeled (24), from micelles (25), polymeric NPs 
(26), liposomes (27), nanocapsules (28), or dendrimers (29), 
to inorganic ones (30). Most of the applications have been in 
cancer imaging and/or therapy (17), but some applications in 
cardiovascular (20, 23) and inflammation/infection (31, 32) can 
be found. Radiolabeling NPs enables the following of the NPs 
in vivo (33), particularly as an image-guided system for targeted 
delivery (34, 35), or for the controlled delivery of a therapeutic 
radionuclide (36).
Due to its favorable physical and chemical properties, such as 
its 6-h half-life, its low energy gamma emission of 140 keV, and 
relatively low isotope cost, generator-produced technetium-99m 
(99mTc) has been the most used radionuclide in routine nuclear 
medicine and is still the subject of numerous investigations, in 
the search for new radiopharmaceuticals. Logically, attempts to 
label NPs with 99mTc have been done (26, 30, 37). 99mTc has also the 
advantage of being part of a matched pair with rhenium-186/188, 
two isotopes that could be used as therapeutic radionuclides. 
Rhenium-188 (188Re), which is also conveniently generator-
produced, like 99mTc, has great potential for radionuclide therapy 
(38, 39). Moreover, due to similar chemistries, it can be easily 
replaced with rhenium-188 (Eβmax = 2.1 MeV, Eγ = 155 keV (15%), 
t1/2 = 17 h) for therapy purposes (40–42).
Because of the growing interest in the site-specific and con-
trolled delivery of radionuclides, we investigated the possibilities 
to entrap a lipophilic radiotracer, 99mTc-SSS, inside NPs based 
on PEG42-b-PMLABe73 or Biot-PEG66-b-PMLABe73. Several 
methods were used to encapsulate 99mTc-SSS with more or less 
success. The corresponding radiolabeled NPs were characterized 
in terms of encapsulation efficiency, diameters, polydispersities, 
zeta potentials, and morphology.
Materials and Methods
Materials
Nuclear magnetic resonance spectra (1H NMR) were recorded 
at 400 MHz on a Brucker ARX400 instrument (Billerica, MA, 
USA). Data are reported as follows: chemical shift (multiplic-
ity, number of hydrogen). The chemical shifts (δ) are reported 
as parts per million (ppm) referenced to the appropriate 
residual solvent peak. Abbreviations are as follows: s (singlet), 
September 2015 | Volume 2 | Article 633
Lepareur et al. 99mTc-loaded functional polymeric nanoparticles
Frontiers in Medicine | www.frontiersin.org
d (doublet), t (triplet), q (quartet), dd (doublet of doublet), m 
(multiplet).
Weight average molecular weight (Mw) and molecular 
weight distribution (Mw/Mn  =  Ip) values were determined 
by size exclusion chromatography (SEC) in THF at 40°C (flow 
rate = 1.0 mL⋅min−1) on a GPC 2502 Viscotek apparatus (Malvern 
Instruments Ltd, Malvern, UK) equipped with a refractive index 
detector, a LT5000L mixed medium org 300 mm × 7.8 mm gel 
column and a GPC/SEC OmniSEC software. The polymer sam-
ples were dissolved in THF (2 mg⋅mL−1). All elution curves were 
calibrated with poly(styrene) standards.
The dynamic light scattering (DLS) measurements were 
recorded on a Delsa™ Nano Beckman Coulter apparatus 
(Fullerton, CA, USA) at 25°C in water. The obtained correlation 
curve allows calculating the diffusion coefficient (D) using the 
CONTIN method. The hydrodynamic radius (Rh), and therefore 
the hydrodynamic diameter (Dh), is then calculated from this dif-
fusion coefficient D using the Stokes–Einstein equation where k 
is the Boltzmann constant, T the temperature, and η the medium 
viscosity (fixed at 0.8878 cP): D = kT/6πηRh.
The zeta potential was measured by zetametry using a Delsa™ 
Nano Beckman Coulter apparatus (Fullerton, CA, USA) at 25°C 
in water. Laser Doppler electrophoresis in a phase mode was 
conducted with sequential fast and slow field reversal applying a 
potential of ±150 V. The measured electrophoretic mobility (μ) 
was then converted to zeta potential using the Smoluchowski 
approximation.
Transmission electron microscopy (TEM) was realized using a 
Jeol 2100 LAB6 microscope (Peabody, MA, USA) equipped with 
a Gatan Orius 200D camera (Pleasanton, CA, USA). UV spectra 
were recorded on a Secomam apparatus (Alès, France) at 485 nm. 
Activity measurements were done in a CRC-127R well-counter 
(Capintec Inc., Ramsey NJ, USA).
Radiochemical purity (RCP) of the complex was determined 
using a Perkin-Elmer Cyclone Storage Phosphor Imager (Waltham, 
MA, USA), with the Packard Optiquant v05.00 software. All 
chemicals were used as received. Anhydrous THF was obtained 
by distillation over sodium/benzophenone under N2 atmosphere.
synthesis of the Monomers and Polymers
The monomer, benzyl malolactonate (MLABe), was synthesized 
from dl-aspartic acid according to the previously reported 
synthesis (43). PEG42-b-PMLABe73 and Biot-PEG66-b-PMLABe73 
block copolymers were obtained by anionic ring opening polym-
erization of MLABe in presence of, respectively, α-methoxy 
ω-carboxy poly(ethylene glycol), PEG42-CO2H, and α-biotin 
ω-carboxy poly(ethylene glycol), Biot-PEG66-CO2H, as initiators 
following a protocol described elsewhere (14).
Peg42-b-PMlaBe73
1H NMR (400.1 MHz; (CD3)2CO), δ (ppm): 2.77–2.83 (m, 2nH, 
CO2CH2C6H5), 3.56–3.59 (m, 4mH (m = 42), CH3O(CH2CH2O)42), 
4.97–5.06 (m, 2nH, CHCH2CO2), 5.39–5.44 (m, 1nH, CHCH2CO2), 
7.19–7.27 (m, 5nH, CO2CH2C6H5). MNMR = 15 860 g/mol for the 
PMLABe block. SEC (THF, polystyrene standards, 1 mL/min): 
Mw = 5 430 g/mol, Ip = 1.38.
Biot-Peg66-b-PMlaBe73
1H NMR (400.1  MHz; (CD3)2CO), δ (ppm): 2.83 (s, 2nH, 
CO2CH2C6H5), 3.56–3.59 (m, 4mH (m = 66), Biot(CH2CH2O)62), 
5.00–5.05 (m, 2nH, CHCH2CO2), 5.41–5.44 (m, 1nH, CHCH2CO2), 
7.19–7.23 (m, 5nH, CO2CH2C6H5). MNMR = 14 630 g/mol for the 
PMLABe block. SEC (THF, polystyrene standards, 1 mL/min): 
Mw = 5 510 g/mol, Ip = 1.45.
Preparation of the nPs
Nanoparticles were prepared by the nanoprecipitation technique 
described previously (14). Briefly, a solution of 5 mg of copolymer 
in acetone was rapidly added to 2 mL of water under vigorous 
stirring. After 10 min of stirring at room temperature, acetone 
was eliminated under vacuum.
A slightly modified nanoprecipitation procedure (Gel filtra-
tion method) was also used: 5 mg of block copolymer were dis-
solved in 100 μL of DMF or acetone and 50 μL of DMF or acetone, 
containing or not the 185/187Re[PhCS3)2(PhCS2)] (185/187Re-SSS) 
prepared as previously described (40), were added. The DMF 
or acetone solution was rapidly added into 1 mL of water under 
vigorous stirring. This solution was stirred at room temperature 
for 1  h, passed through a gel filtration PD-10 Sephadex G-25 
Medium column (GE Healthcare, Little Chalfont, UK) and eluted 
with 1.5 mL + 3.5 mL of water.
characterization of the nanoparticles
The size (average Dh, polydispersity (Đ) and zeta potential of the 
formulations were measured by respectively DLS and zetametry, 
without any dilution of the samples.
Nanoparticles were observed by TEM. NPs’ suspensions in 
water were placed on a formvar–carbon film coated on a copper 
grid (300 mesh). After 6 min of deposition at room temperature, 
non-adherent NPs were eliminated and the sample was stained 
by phosphotungstic acid (0.1%) for 30  s. TEM imaging was 
performed under 80 kV accelerating voltage.
synthesis of 99mTc-sss complex
99mTc-SSS complex preparation was adapted from previously 
described method (44). Briefly, kits containing sodium gluconate 
and tin (II) chloride were first prepared as described thereafter: 
825 mg of sodium gluconate were dissolved in 9.9 mL of distilled 
water. This solution (0.9 mL) was placed into 10 flasks. In parallel, 
8.25 mg of tin chloride (SnCl2.2H2O) were dissolved into 1.1 mL 
of 0.1N HCl solution. Then, 0.1 mL of this solution was added 
in each flask containing the gluconate solution. The flasks were 
lyophilized and crimped.
One milliliter of [99mTc]-pertechnetate (750–800  MBq), 
eluted from a 99Mo/99mTc generator (ELU III, IBA Molecular, 
Gif-sur-Yvette, France) was added to a lyophilized kit containing 
sodium gluconate (75 mg) and SnCl2,2H2O (0.75 mg) prepared 
as described above. The mixture was shaken at room temperature 
for 15 min. Sodium dithiobenzoate (10 mg dissolved into 0.5 mL 
of 0.9% saline solution) was added, and the solution was heated at 
100°C for 15 min. A thin layer chromatography (TLC) was real-
ized in a mixture of hexane and dichloromethane 6/4 as eluent to 
assess RCP of the complex (Rf = 0.62).
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radiolabeling of the nPs
The 99mTc-SSS complex previously prepared was extracted with 
1  mL of dichloromethane. The organic solvent was evaporated 
at 40°C. Two procedures were tested for radiolabeling of the 
NPs according to the ones tested for empty NPs and 185/187Re-SSS 
loaded NPs.
Standard Nanoprecipitation
Acetone or ethanol (0.5  mL) was then added to the residue to 
solubilize the complex, and a solution of 5 mg of the selected block 
copolymers, into 0.5 mL of acetone, was added. The mixture was 
nanoprecipitated into 2  mL of 0.9% saline solution. After stir-
ring, the organic solvent was eliminated by heating at 45°C, under 
slight vacuum, for 15 min. The flask was then centrifuged at 3,500 
G for 20  min (Awel MF 20-R, Blain, France). The supernatant 
was discarded and the pellet containing the radiolabeled NPs was 
resuspended into 2 mL of physiological serum. The radioactivity 
of the flask before and after centrifugation and resuspension was 
measured and the encapsulation efficiency was calculated as the 
ratio of the resuspended pellet activity on total activity before 
centrifugation.
Gel Filtration
DMF or acetone (0.15 mL) was then added to the dried complex. 
Five milligrams of the selected block copolymer were dissolved 
into 100 μL of DMF or acetone and 50 μL of the solution contain-
ing the 99mTc-SSS complex were added. This organic solution was 
then rapidly added into 1 mL of water. The mixture was stirred at 
room temperature for 15 min, passed through a PD-10 Sephadex 
G-25 Medium column and eluted with 1.5 mL + 3.5 mL of water 
as described above. The radioactivity of the flask before and after 
passage on the column was measured and the encapsulation 
efficiency was calculated as the ratio of the collected fraction’s 
activity on total activity before filtration.
After total decrease of the radioactivity, 99mTc-radiolabeled 
NPs were analyzed by DLS to determine their diameter, poly-
dispersity index, and zeta potential. The radiolabeled NPs were 
also observed by TEM after complete radioactive decay following 
the procedure described just above. An energy dispersive X-ray 
spectrometry (EDS) analysis of the radiolabeled NPs was also 
realized during the TEM measurements.
results and Discussion
We have been recently investigating the possibilities of radiolabe-
ling PMLA derivatives-based NPs with the final goal of using such 
nanocarriers for the dual site-specific carrying of a radioelement 
(99mTc/188Re-SSS) and an anti-cancer drug. To reach this objec-
tive, we studied the possibilities to use degradable stealth and/or 
targeted NPs, constituted by PMLA amphiphilic derivatives, for 
radionuclides’ encapsulation.
In a first step, we synthesized two amphiphilic PMLA 
derivatives, PEG42-b-PMLABe73 and Biot-PEG66-b-PMLABe73, 
by anionic ring opening polymerization of the MLABe with, 
respectively, α-methoxy,ω-carboxylate PEG42 and α-biotin,ω-
carboxylate PEG66 as initiator. MLABe was synthesized in four 
steps, starting from aspartic acid, following a well-described and 
reproducible synthetic route (Figure 1) (14–16, 43). After puri-
fication by precipitation, allowing the elimination of unreacted 
initiator and low molecular weight oligomers, block copolymers 
were characterized by 1H NMR (structure and molecular weight 
of the PMLABe block) and by SEC (average molecular weight and 
polymolecularity).
Polymers’ characteristics are summarized in Table 1. For both 
block copolymers, the molecular weights of the PMLABe block 
were calculated from their 1H NMR spectra on the basis of the 
integration of peaks corresponding to the PEG block, whose 
molecular weight is given by the supplier, and on the integra-
tion of peaks corresponding to the PMLABe block. Calculated 
molecular weights were very similar to theoretical ones chosen 
at 15,000  g/mol and fixed by the monomer/initiator ratio. On 
the other hand, the average molecular weights measured by 
SEC were lower than the block copolymers’ global molecular 
weights, calculated from the PEG and PMLABe molecular 
weights, resulting from the fact that THF is not the best solvent 
for the block copolymers and that the measured molecular 
FigUre 1 | synthetic route to Peg42-b-PMlaBe73 and Biot-Peg66-b-
PMlaBe73.
TaBle 2 | characteristics of empty and 185/187re-sss loaded PMlaBe 
derivatives-based nPs.
nPs hydrodynamic 
diameter (nm)a
Polydispersity 
index (Đ)a
Zeta 
potential 
(mV)b
Peg42-b-PMlaBe73
Standard nanoprecipitation 
method with acetone
80 0.06 −6
Gel filtration with acetone 113 0.17 −31
Gel filtration with DMF 99 0.11 −29
Biot-Peg66-b-PMlaBe73
Standard nanoprecipitation 
method with acetone
65 0.12 −7
Standard radiolabeling 
method with acetone
80 0.21 –
Gel filtration with acetone 87 0.20 −26
Gel filtration with DMF 68 0.15 −30
Peg42-b-PMlaBe73[185/187re-sss]
Gel filtration with acetone 174 0.17 −37
Gel filtration with DMF 104 0.14 −32
Biot-Peg66-b-PMlaBe73[185/187re-sss]
Gel filtration with acetone 135 0.18 −25
Gel filtration with DMF 99 0.15 −39
aMeasured by dynamic light scattering (DLS).
bMeasured by zetametry.
TaBle 1 | characteristics of the synthesized block-copolymers.
Block copolymers MPega  
g/mol
MPMlaBeb  
g/mol
Mwc  
g/mol
ipc
PEG42-b-PMLABe73 2 015 15 860 5 430 1.38
Biot-PEG66-b-PMLABe73 3 274 14 630 5 510 1.45
aGiven by the supplier (PEG IrisBiotech).
bDetermined by 1H NMR using the relative intensity of protons of PEG and PMLABe 
blocks.
cMeasured by size exclusion chromatography (SEC) in THF at 40°C with poly(styrene) 
standards (1 mL/min, RI detector).
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weights are related to polystyrene standards having a different 
macromolecular structure than the one of PMLA derivatives. 
However, SEC analysis allows determining the molecular weight 
distribution (Ip =  Mw/Mn) and verifying the obtaining of a 
block copolymer (only one peak). In our study, SEC chroma-
tograms of both block-copolymers highlighted the presence of 
only one macromolecular species (only one peak) and a good 
control of the polymerization reaction, as shown by the quite 
low polymolecularity of the samples (Ip < 1.5) in light of these 
results, we were able to obtain well-defined block copolymers 
suitable to continue the study of NPs’ preparation. However, we 
still have to further characterize the block copolymers, especially 
to determine their thermal properties (Tg, Tm) by differential 
scanning calorimetry (DSC), which gives an insight on the 
copolymer state (rubber or glassy state). Nevertheless, we can 
have a primary idea of the block copolymer’s thermal properties 
since it should have both the thermal properties of each block, 
i.e., the ones of PEG (Tg = −20°C, Tm = 50°C) and the ones of 
PMLABe (Tg = 37°C).
Nanoparticles can be easily and reproducibly prepared from 
these amphiphilic block copolymers by the nanoprecipitation 
technique, consisting in a rapid addition of a water miscible sol-
vent, in which the block copolymer was dissolved, to an aqueous 
solution under vigorous stirring at 20°C (14–16).
For the standard method, acetone was eliminated under 
vacuum, while for the gel filtration method, empty NPs and 
185/187Re-SSS loaded NPs were passed through a PD-10 Sephadex 
G-25 Medium column. The prepared NPs were analyzed by: 
(i) DLS, giving access to the average Dh and polydispersity (Đ), 
(ii) Zetametry, giving access to the surface charge of the NPs, and 
by (iii) TEM, allowing determining the NPs’ morphology.
As shown by results gathered in Table 2, both the standard 
nanoprecipitation method with acetone and the gel filtration 
method (with DMF) allowed preparing both stealth and targeted 
NPs with Dhs varying between 65 and 99 nm with a quite small 
size distribution (Đ lower than 0.15), highlighting the formation 
of well-defined nano-objects in good agreement with the size 
of micelle-liked NPs (45). On the other hand, the gel filtration 
method with acetone led to larger NPs with a higher dispersity 
(Đ around 0.2). However, the values stayed acceptable. The 
radiolabeling procedure was first tested with the non-radioactive 
185/187Re-SSS complex. The preparation of 185/187Re-SSS loaded NPs 
by the standard nanoprecipitation method with acetone led to 
the formation of large aggregates with quite large size distribu-
tion (data not shown) and was not further used in this study. 
Therefore, we used the gel filtration method to load the 185/187Re-SSS 
complex inside the NPs. As shown by results given in Table 2, gel 
filtration with DMF allowed obtaining quite well-defined NPs 
(low Đ) with a slightly increased Dh, probably as a result of the 
presence of the complex inside de NPs. On the contrary, with 
acetone, it led to larger NPs with higher polydispersity indexes. 
At this stage, we can conclude that gel filtration with DMF seems 
to lead to the best results in terms of size and size distribution. 
Stirring the solution for 15 min, instead of 1 h leads to not as 
good results (Dhs and Đ, respectively, 144 nm vs. 104 and 0.19 
vs. 0.14 for 185/187Re-SSS loaded PEG42-b-PMLABe73 in DMF), but 
it is better suited for the encapsulation of technetium-99m, due 
to radioactive decay considerations, and values are still satisfac-
tory. The NPs prepared by the gel filtration methods (acetone 
and DMF) loaded or not with the 185/187Re-SSS complex have 
zeta potentials around −30 mV highlighting a negative surface 
charge which can be associated with a good stability of the cor-
responding NPs. Such negative surface charges can be the result 
of a block copolymer chain conformation allowing the presence 
of carboxylate end groups of the PMLABe block at the surface of 
the NPs thus lowering the values of the zeta potential. However, 
further experiments (static light scattering, Cryo-TEM, etc.) 
are needed to determine the morphology of the NPs and if any 
change can be observed in function of the preparation procedure 
used to obtain the NPs.
In parallel, the selected radioactive complex 
[99mTc(PhCS3)2(PhCS2)] (99mTc-SSS) has been prepared in two 
steps, starting from the generator-eluted pertechnetate ion, 
[99mTcO4]−, in 0.9% saline solution (Figure  2) (44). 99mTc-SSS 
complex was obtained with a RCP over 90%.
After those steps, we had to set up a simple and reproducible way 
of radiolabeling PEG42-b-PMLABe73 or Biot-PEG66-b-PMLABe73 
TaBle 3 | characteristics of radiolabeled PMlaBe derivatives-based nPs.
nPs encapsulation 
efficiency (%)a
hydrodynamic  
diameter (nm)b
Polydispersity  
index (Đ)b
Zeta potential  
(mV)b
Peg42-b-PMlaBe73 [99mTc-sss]
Standard nanoprecipitation method with acetone 61 230 0.15 +0.2
Gel filtration with acetone 89 121 0.22 −37
Gel filtration with DMF 86 103 0.16 −38
Biot-Peg66-b-PMlaBe73 [99mTc-sss]
Standard nanoprecipitation method with acetone 82 160 0.23 −4.3
Gel filtration with acetone 87 118 0.16 −16
Gel filtration with DMF 89 249 0.22 −25
aDetermined by radioactivity measurement.
bMeasured by DLS (Delsa Nano® Beckman Coulter).
FigUre 2 | synthesis of the 99mT-sss radiocomplex.
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based NPs. In a first attempt, we tried to encapsulate the 99mTc-SSS 
complex in already formed NPs, previously obtained by the nano-
precipitation technique as described above. However, we were 
not able to encapsulate the complex inside the preformed NPs 
because of their destabilization by the reducing agent which is 
present in the kits used for the complex formation. Consequently, 
it was necessary to extract the complex in dichloromethane in 
order to eliminate the kit constituents. Dichloromethane was 
then evaporated and the radiotracer retaken in a water-miscible 
organic solvent, then added to the acetone or DMF solution con-
taining PEG42-b-PMLABe73 or Biot-PEG66-b-PMLABe73 block 
copolymers.
To determine the encapsulation efficiency, we have measured 
the NPs’ radioactivity. For that, we have eliminated the non-
encapsulated complex:
- either by centrifugation in the case of the standard nanopre-
cipitation using acetone: the supernatant was discarded and 
the pellet was again suspended into physiological serum. The 
total radioactivity of the flask before and after centrifugation 
and the radioactivity of the supernatant were measured. The 
encapsulation efficiency was given by the ratio between the 
radioactivity of the flask before centrifugation and the radio-
activity of the flask after centrifugation and resuspension of 
NPs (Table 3). Some trials have been done with ethanol to 
solubilize 99mTc-SSS after dichloromethane evaporation, but 
this solvent is more difficult to evaporate than acetone, so the 
latter one was preferred.
- or by gel filtration through a PD-10 Sephadex G-25 Medium 
column. The total radioactivity of the flask before and after 
Sephadex filtration were measured and allowed to calculate 
the encapsulation efficiency (ratio between the radioactivity 
of the flask before and after filtration) (Table 3).
After the radioactivity decay, Dhs, polydispersity indexes, and 
zeta potentials of the complex-containing NPs were measured 
by DLS. As shown by results gathered in Table 3, 99mTc-SSS com-
plex was successfully encapsulated in both PEG42-b-PMLABe73 
and Biot-PEG66-b-PMLABe73 based NPs, using standard 
nanoprecipitation technique, with an encapsulation efficiency 
varying between 60 and 80%. Non-PEGylated PMLABe based 
NPs were also investigated to encapsulate 99mTc-SSS, but the 
resulting labeled NPs were not sufficiently stable in time to be 
studied after radioactivity decay. The radiolabeled NPs, obtained 
through the standard labeling method, present increased diam-
eters with identical low polydispersity indexes, typically in the 
0.15–0.23 range, and neutral zeta potentials in comparison to 
non-radiolabeled NPs (Table 3). Several reasons can explain the 
increase of the diameters measured by DLS: (i) a swelling of the 
inner-core by remaining acetone which is quite difficult to totally 
eliminate in the experimental conditions of the standard nano-
precipitation procedure used to prepare radiolabeled NPs, (ii) 
the presence of the radiotracer itself, or (iii) an aggregation of the 
NPs during the time necessary for radioactivity decay (3 days). 
Except for the simple PMLABe NPs, the NPs demonstrated good 
in vitro stability, with no size change over time (Table 4). Thus, 
the increase in size cannot be explained by the delay for the 
radioactivity to decay before measurements. The results obtained 
on empty NPs prepared using the same protocol than the one 
used for the preparation of radiolabeled NPs (standard radiola-
beling method), and with NPs encapsulating non-radioactive 
complex based on “cold” 185/187Re evidenced that the presence of 
the complex leads to an increase of the NPs’ diameters without 
aggregation (Table 2). However, because the total elimination of 
acetone is quite difficult with the radioactive complex and cen-
trifugation procedure is not satisfactory, with NPs still present 
in the supernatant, as evidenced by DLS measurements, thus 
FigUre 3 | TeM images of (a) empty Biot-Peg66-b-PMlaBe73 based 
nPs and (B) radiolabeled Biot-Peg66-b-PMlaBe73 based nPs.
TaBle 4 | Over-time stability of PMlaBe derivatives-based nPs 
(measured by Dls).
nPs hydrodynamic 
diameter (nm)
Polydispersity  
index (Đ)
Peg42-b-PMlaBe73
D0 (acetone) 113 0.17
D7 (acetone) 119 0.13
D0 (DMF) 99 0.11
D7 (DMF) 105 0.10
Biot-Peg66-b-PMlaBe73
D0 (acetone) 87 0.20
D7 (acetone) 87 0.19
D0 (DMF) 68 0.15
D7 (DMF) 88 0.15
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probably minoring encapsulation yields, we tried to purify the 
radiolabeled NPs by dialysis. However, such method was time 
consuming, which is crippling with short half-life radionuclides, 
and led to no better results than centrifugation, so this method 
was not pursued.
We therefore used the gel filtration method to prepare radiola-
beled NPs. Using this gel filtration procedure, we also observed 
larger Dhs with slightly higher polydispersity index values 
compared to empty NPs (Table  3). This increase in diameters 
is probably the result of the radiotracer encapsulation, because 
no significant differences were observed in diameter and poly-
dispersity index values between the standard nanoprecipitation 
procedure and the gel filtration method (Table 2). However, the 
encapsulation efficiencies seem to be slightly higher when gel 
filtration method is used either with acetone or DMF, with encap-
sulation yields between 86 and 89%. Moreover, this procedure is 
faster and easier to set up than the standard nanoprecipitation 
method because no centrifugation is necessary, thus avoiding the 
difficulties to separate the supernatant and the pellet. As observed 
previously with empty NPs, this method led to NPs with negative 
zeta potentials despite the PEG chains. As already mentioned, 
further experiments will be done to understand the reasons for 
this observed phenomenon which is probably related to the chain 
conformation adopted by the block copolymer as mentioned 
above.
Both empty and radiolabeled NPs, after radioactivity decay, 
were analyzed by TEM in order to have an idea of their morphol-
ogy (Figure 3).
Indeed, DLS allows only measuring Dh and size distribu-
tion without having access to NPs’ morphology. As shown by 
Figure 3, both empty and radiolabeled NPs, prepared with the 
standard method, have a spherical shape with a diameter in good 
agreement with the Dhs measured by DLS: around 80  nm for 
empty NPs and 120 nm for radiolabeled NPs. Moreover, an EDS 
analysis of the radiolabeled NPs was also realized during the 
TEM measurements: this technique allows the determination of 
the elements present in the analyzed sample (46). EDS analysis 
evidenced the presence of sulfur inside the NPs, reflecting the 
presence of the 99mTc-SSS complex which contains sulfur atoms. 
On the contrary, EDS analysis realized on empty NPs did not 
highlight any presence of sulfur atoms. Therefore, it tends to 
prove that the 99mTc-SSS complex is effectively encapsulated 
inside the NPs constituting by PMLA derivatives. TEM experi-
ments now need to be done on NPs prepared using the alternative 
gel filtration method to get more insight on the influence of the 
preparation method on NPs morphology.
conclusion
Through this study, we highlighted that it is possible to obtain 
radiolabeled NPs based on PEGylated or biotinylated PEGylated 
degradable block copolymers with quite high encapsulation 
efficiency (up to 89%) in an easy and reproducible way. The 
radiolabeled NPs were characterized by Dhs ranging from 100 
to 230 nm with quite low polydispersity indexes (under 0.2) and 
negative zeta potentials. The morphology of such NPs was shown 
to be spherical and the presence of sulfur, resulting from 99mTc-
SSS complex, was detected inside the NPs.
We are now moving to 188Re-SSS encapsulation and in vitro 
assays to confirm the potential of stealth and targeting NPs based 
on PMLABe derivatives as therapeutic nanovectors. Since our 
team has been working on DOX’s encapsulation and the grafting 
of a fluorescent probe too, we likewise envision to combine these 
different approaches as potential theranostic tools of interest for 
combined chemo-/radiotherapy and/or bimodal imaging probes 
for instance.
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